HundredX recently analyzed trends in customer sentiment for Walgreens versus competitors through May 2023. The analysis draws on over 68,000 pieces of continuous, double-blind customer feedback across the Pharmacy category since May 2022, including over 27,000 on Walgreens.

Key Takeaways:

  • Analyzing customer insights, we saw the way companies dealt with staffing show up as a key differentiator for the industry.


  • Walgreens has lost its leadership position in Purchase Intent1,2 since February 2023, declining 3%, while competitors Kroger and Costco Pharmacy increased 3% and 5% over the same period.


  • Walgreens has experienced a 4% decline in customer sentiment3 toward Pharmacy since February 2023, coinciding with staff shortages across the pharmacy industry.


  • Walgreens customers have complained about its understaffed pharmacy, which has led to long lines and wait times, slow checkouts, unavailable prescriptions, and overworked pharmacists.


  • Kroger Pharmacy has experienced an increase in customer sentiment towards Speed/Checkout (+7%), Pharmacy (+5%), and Price (+5%) since February 2023.


  • Costco Pharmacy’s customer sentiment has increased for Attitude and Pharmacy since March 2023, increasing 12% and 5%, respectively, while Price has improved by 10% since January 2023.


Discover HundredX insights into Walgreens and the pharmacy industry:

Please contact our team for a deeper look at HundredX's data on Pharmacies, which includes more than 130,000 pieces of customer feedback across 12 pharmacy brands.


  1. All metrics presented, including Net Purchase Intent (Purchase Intent) and Net Positive Percent / Sentiment are presented on a trailing three-month basis unless otherwise noted.
  2. Purchase Intent for retail subsectors, including pharmacies, represents the percentage of customers who expect to spend more with that brand over the next 12 months, minus those that intend to spend less.
  3. HundredX measures sentiment towards a driver of customer satisfaction as Net Positive Percent (NPP), which is the percentage of customers who view a factor as a positive (reason they liked the products, people, or experiences) minus the percentage who see the same factor as a negative.

Strategy Made Smarter


HundredX works with a variety of companies and their investors to answer some of the most important strategy questions in business:

  • Where are customers "migrating"?
  • What are they saying they will use more of in the next 12 months?
  • What are the key drivers of their purchase decisions and financial outcomes?


Current clients see immediate benefits across multiple areas including strategy, finance, operations, pricing, investing, and marketing.


Our insights enable business leaders to define and identify specific drivers and decisions enabling them to grow their market share.


Please contact our team to learn more about which businesses across 75 industries are best positioned with customers and the decisions you can make to grow your brand’s market share.

####


HundredX is a mission-based data and insights provider. HundredX does not make investment recommendations. However, we believe in the wisdom of the crowd to inform the outlook for businesses and industries. For more info on specific drivers of customer satisfaction, other companies within 75+ other industries we cover, or if you'd like to learn more about using Data for Good, please reach out: https://hundredx.com/contact.

Share This Article

Starbucks shows weakness as consumers feel worse about taste

06 May, 2024
Sure, lattes, mochaccinos, and cappuccinos are pricey, but they taste delicious. For many consumers, the great taste of coffee shop coffee made it worth the cost. But customers at Starbucks aren't so sure the tradeoff is worth it anymore. Examining more than 420,000 pieces of feedback across the Quick, Fast, Casual (QFC) industry, including over 21,000 on Starbucks, we find: Starbuck's Purchase Intent 1,2 is down 3% over the past six months, with most of that dip occurring over the past few months. By contrast, Dunkin' Donuts has remained within a tight range over the past six months, as did an average of other, smaller coffee chains. Customers increasingly see less value in Starbucks. Starbuck's Value perception 3 fell 5% over the past six months, compared to just 1% for Dunkin' Donuts. However, it also fell 5% for the average of the smaller coffee chains. Coffee drinkers feel significantly unhappier about Starbuck's quality and taste. Starbuck's Taste perception fell 4% over the past six months, while rising 1% for competitors. Likewise, its Quality perception dipped 3% over the same time period (and 8% over the year). Ultimately, Starbuck's perceived drop in taste is leading inflation-weary consumers to say they plan to spend less at the coffee chain, as the value just isn't as good.

Forbes Announces Best Brands for Social Impact List 2024 Powered by HundredX

06 May, 2024
Forbes Best Brands for Social Impact, Powered by HundredX

Mounjaro maintains top spot among GLP-1 drugs

06 May, 2024
Ozempic once dominated the headlines, but GLP-1 competitor Mounjaro is winning over customers. GLP-1 drugs, used for treating diabetes and aiding in weight loss, are relatively new on the market yet have surged in popularity over the last year. They're becoming so popular that J.P. Morgan estimates that 30 million people in the US may be using a GLP-1 drug by 2030. This statistic presents a significant potential for early drug creator Novo Nordisk (Ozempic, Wegovy), and perhaps an even bigger one for Eli Lilly (Mounjaro, Zepbound). HundredX data indicates Eli Lilly is in a position to win over Novo Nordisk as Mounjaro's Usage Intent widens against the competition. Ozempic may have name recognition, but customers feel more positively about Mounjaro's effectiveness and lifestyle impact, even if they aren't excited about its high price. Examining 1,500 pieces of customer feedback across Mounjaro, Ozempic, and Wegovy, we find: GLP-1 users increasingly say they plan to use Mounjaro more, and Ozempic less . Mounjaro’s Usage Intent is up 19% since July, Wegovy’s is up 3%, and Ozempic has stayed within a tight range. Customers feel Mounjaro is more effective than competing drugs, but it’s harder to get . Mounjaro outperforms other GLP-1 drugs in effectiveness, lifestyle impact, and side effects. However, customers dislike its cost and availably more than competitors.
Share by: